GEB-101の遺伝子組み換え療法で視力喪失を生じる 貴重な眼疾患の遺伝子組み換え治療です GenEditBio gets FDA go-ahead for human trials of GEB-101, a genome-editing therapy for a rare eye disease causing vision loss.

GENDBOは,米FDAの承認を得て,GEB-101の臨床試験を開始した. GenEditBio has received approval from the U.S. FDA to begin clinical trials for GEB-101, its in vivo genome-editing therapy targeting TGFBI corneal dystrophy, a rare genetic eye disorder causing vision loss. FDAの調査新薬 (IND) 申請の承認により,同社はヒトでの試験を開始することができ,この疾患の治療の可能性に向けた重要な一歩となる. The FDA’s clearance of the Investigational New Drug (IND) application allows the company to initiate human testing, marking a significant step toward potential treatment for the condition.